Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E287118-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $27.90 | |
E287118-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $82.90 | |
E287118-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $147.90 | |
E287118-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $332.90 | |
E287118-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $598.90 |
Potent and selective PPARγ agonist; antidiabetic
Synonyms | Edaglitazone|213411-83-7|5-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)methyl)thiazolidine-2,4-dione|Edaglitazone [INN]|Edaglitazone, (+)-|Edaglitazone, (-)-|QP6GWW0LZD|59LQZ96XUU|BM 131258|BM-131258|8GKF7V499B|BM13.1258|R 483|R-483| |
---|---|
Specifications & Purity | Moligand™, ≥95% |
Biochemical and Physiological Mechanisms | Potent and selective PPARγagonist (EC50values are 35.6 and 1053 nM for PPARγand PPARαcofactor recruitment respectively. Enhances insulin sensitivity in obese, but not lean, rats. Antidiabetic and orally bioavailable. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of Peroxisome proliferator-activated receptor-α;Agonist of Peroxisome proliferator-activated receptor-γ |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 5-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]methyl]-1,3-thiazolidine-2,4-dione |
---|---|
INCHI | InChI=1S/C24H20N2O4S2/c1-14-18(25-23(30-14)15-5-3-2-4-6-15)9-11-29-19-8-7-16(21-17(19)10-12-31-21)13-20-22(27)26-24(28)32-20/h2-8,10,12,20H,9,11,13H2,1H3,(H,26,27,28) |
InChi Key | HAAXAFNSRADSMK-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC5C(=O)NC(=O)S5 |
Isomeric SMILES | CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC5C(=O)NC(=O)S5 |
PubChem CID | 9825701 |
Molecular Weight | 464.56 |
PubChem CID | 9825701 |
---|---|
CAS Registry No. | 213411-83-7 |
RCSB PDB Ligand | 8A7 |
Enter Lot Number to search for COA:
Solubility | Solvent:DMSO, Max Conc. mg/mL: None, Max Conc. mM: 100 |
---|---|
Sensitivity | Moisture Sensitive |
1. Fürnsinn C, Brunmair B, Meyer M, Neschen S, Furtmüller R, Roden M, Kühnle HF, Nowotny P, Schneider B, Waldhäusl W. (1999) Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism.. Br J Pharmacol, 128 (6): (1141-8). [PMID:10578125] |
2. Dietz M, Mohr P, Kuhn B, Maerki HP, Hartman P, Ruf A, Benz J, Grether U, Wright MB. (2012) Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.. ChemMedChem, 7 (6): (1101-11). [PMID:22489042] |